Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Related Clinical Trial
MAP to Provide Access to Nilotinib, for Patients With HES Eosinophilia Diagnosis A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Steroid Treatment for Hypereosinophilic Syndrome Natural History of Hypereosinophilia and Hypereosinophilic Syndromes A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Identification of New Markers in the Hypereosinophilic Syndrome A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Brief Title

Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Official Title

Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes

Brief Summary

      The study was performed to assess: 1) clinical activity of Imatinib in patients with HES, CEL
      and CIH; 2) correlation between Imatinib activity and specific disease subtype; 3) long-term
      outcome of HES, CEL and CIH patients treated with Imatinib; 4) safety and tolerability of
      Imatinib administration.

Detailed Description

      Hypereosinophilic syndrome (HES), chronic eosinophilic leukaemia (CEL) and chronic idiopathic
      hypereosinophilia (CIH) are rare disorders characterized by chronic hypereosinophilia with
      possible damage to various organs due to eosinophilic infiltration and release of cytokines.
      The therapies of these diseases are largely unsatisfactory and based on the use of a variety
      of antiproliferative drugs such as corticosteroids, interferon-alfa, cyclosporine,
      vincristine or hydroxyurea. More often the responses are transient and patients need numerous
      treatment lines.

      In 2001 Schaller et al reported the first case of a patient with HES resistant to
      conventional treatment that responded to imatinib mesylate. (Schaller, MGM 2001). After that,
      many authors described cases with hypereosinophilia that achieve a rapid response to Imatinib
      and in 2003 Cools et al identified a novel tyrosine kinase generated from the fusion of the
      Fip1-like 1 (FIP1L1) gene to the PDGFRalfa gene associated to hypereosinophilia.

      The optimal dose of Imatinib in this setting of patients is still unknown; however, the
      demonstration of effective and safe clinical doses in a variety of currently studied
      malignant diseases, suggests that a dose of 100 mg/day increasing weekly of 100 mg/day
      (maximum dose 400 mg/day), may be employed.

      We designed a phase II trial to investigate the clinical anti-proliferative activity, safety
      and tolerability of escalating doses of Imatinib (entry dose 100 mg/d)administered for 12
      total weeks in HES, CEL and CIH patients.

Study Phase

Phase 2

Study Type


Primary Outcome

Response rate

Secondary Outcome

 Safety: Adverse events and serious adverse events


Hypereosinophilic Syndrome



Study Arms / Comparison Groups

Description:  Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 2004

Completion Date

December 2007

Primary Completion Date

December 2007

Eligibility Criteria

        Inclusion Criteria:

          -  patients with a diagnosis of HES, CEL and CIH, who are either previously untreated or
             have been treated with corticosteroids, cytotoxic drugs, and IFN.

          -  age > 15 years.

          -  signature of a written informed consent(by parents/tutors for patients aged < 18

        Exclusion Criteria:

          -  patients with a diagnosis of secondary hypereosinophilia

          -  age < 15 years




15 Years - N/A

Accepts Healthy Volunteers



Renato Bassan, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs

EUDRACT 2004-002280-24

Study Sponsor

Northern Italy Leukemia Group

Study Sponsor

Renato Bassan, MD, Principal Investigator, USC Ematologia Ospedali Riuniti di Bergamo

Verification Date

December 2010